Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Long-term Investments

Investments the company intends to hold for more than a year.

Seer, Inc.NASDAQ: SEER

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments rises 15.9% from a year ago

Long-term investments stood at $52.85M at the end of Q1 FY2026, up 15.9% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at +119.7% a year.

Context

  • Long-term investments amounted to 19.4% of total assets at the end of Q1 FY2026, up 6.3 pp from a year earlier.
  • Long-term investments increased in 2 of the last 3 fiscal years.

What to watch

Whether long-term investments keeps rising in the next quarterly balance sheet after a +15.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$52.85M-3.4% QoQ
Last fiscal yearDec 2025
$54.69M-13.3% YoY
Year agoMar 2025
$45.58M+15.9% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.9%——
1 year-13.3%——
3-year CAGR+119.7%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

USD · from the balance sheet

Latest · FY2025
54.69M USD
Year-over-year change
-13.3%
4-year CAGR
-12.5%

Long-term Investments vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +15.9% is the 4th highest of 8, against a peer median of -59.9%.
  • Long-term investments amounts to 19.4% of total assets for SEER, versus a peer median of 0.9%.
SEER Competitors
Long-term Investments for SEER and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KYMRKymera Therapeutics, Inc.Jun 2026$813.9M USD+168.2%+72.1%49.5%
ORICORIC Pharmaceuticals, Inc.Mar 2026$137.78M USD+587.6%+70.6%31.5%
QSIQuantum-Si incorporatedMar 2026$63.02M USD——29.5%
SEERSeer, Inc.Mar 2026$52.85M USD+15.9%+119.7%19.4%
CGEMCullinan Therapeutics, Inc.Mar 2026$38.5M USD-85.2%-10.4%9.6%
CCCCC4 Therapeutics, Inc.Mar 2026$36.04M USD+83.7%-7.3%11.0%
NKTXNkarta, Inc.Mar 2026$33.57M USD-59.9%+80.4%9.0%
LYELLyell Immunopharma, Inc.Mar 2026$19M USD-60.4%-45.1%5.4%
NRIXNurix Therapeutics, Inc.Aug 2026$14.83M USD——1.2%
FHTXFoghorn Therapeutics Inc.Mar 2026$2M USD——0.9%
STTKShattuck Labs, Inc.Mar 2026$1M USD——1.0%
PHVSPharvaris N.V.Sep 2026€0 EUR——0.0%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 USD——0.0%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$0 USD——0.0%
SANASana Biotechnology, Inc.Mar 2026$0 USD——0.0%
PEPGPepGen Inc.Mar 2026$0 USD——0.0%
ANTXAN2 Therapeutics, Inc.Mar 2026$0 USD-100.0%-14.5%0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
MNOVMediciNova, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding SEER) —-59.9%-7.3%0.9%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.81M53.21M32.5M40.75M47.29M
Short-term Investments167.26M368.03M283.73M195.66M138.61M
Net Receivables4.14M7.02M6.72M6.23M5.95M
Inventory4.15M4.63M4.49M7.44M7.8M
Other Current Assets02.1M3.08M3.25M1.89M
Total Current Assets411.7M434.98M330.51M253.32M201.53M
Property, Plant & Equipment (Net)33.23M46.41M47.37M41.37M35.24M
Goodwill00000
Intangible Assets00000
Long-term Investments93.19M5.16M56.86M63.1M54.69M
Tax Assets00000
Other Non-current Assets1.03M1.38M1.53M8.81M4.62M
Total Non-current Assets127.44M52.95M105.76M113.27M94.55M
Total Assets539.14M487.93M436.27M366.6M296.08M
Account Payables3.79M2.1M1.37M4.62M5.61M
Short-term Debt002.3M2.31M0
Tax Payables457K335K501K471K0
Deferred Revenue376K133K206K408K341K
Other Current Liabilities4.73M6.35M2.73M1.54M5.63M
Total Current Liabilities13.42M12.58M13.22M15.33M15.69M
Long-term Debt000021.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities341K320K179K48K8K
Total Non-current Liabilities22.8M28.35M26.14M23.7M21.09M
Total Liabilities36.22M40.94M39.37M39.03M36.78M
Common Stock1K1K1K1K1K
Retained Earnings(126.53M)(219.5M)(305.77M)(392.37M)(465.97M)
Accumulated OCI(536K)(1.25M)(192K)136K459K
Other Stockholders Equity00000
Minority Interest00000
Total Equity502.92M446.99M396.9M327.57M259.31M
Total Debt23.32M29.87M28.26M25.96M23.65M
Net Debt(209.49M)(23.33M)(4.24M)(14.79M)(23.63M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.